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Familial Abdominal Aortic Aneurysm: a Systematic Review of
a Genetic Background
C. J. van Vlijmen-van Keulen1, G. Pals2 and J. A. Rauwerda1
1Institute for Cardiovascular Research and 2Department of Clinical Genetics, Vrije Universiteit
Medical Center, Amsterdam, The Netherlands
Background: familial clustering of the abdominal aortic aneurysm (AAA) is clear, 12±19% of AAA patients have one or
more first-degree relatives with an aneurysm and 4±19% is detected with ultrasound screening.
Objectives: to review the genetic background of AAA.
Design, methods and materials: computer searches of the MEDLINE, EMBASE, SUMsearch database and the Cochrane
Library and searched reference lists of English language articles concerning the genetics of AAA, candidate gene approach
and linkage analysis.
Results: brothers of AAA patients are at high risk to develop an AAA. The candidate gene approach was performed to
detect defects in one of the components of the connective tissue, i.e. type I and III collagen, elastin and fibrillin, the
inflammatory cell-derived matrix metalloproteinase, there inhibitors, auto-immune components and components related to
atherosclerosis.
Conclusion: these studies give us insight in the pathology but do not lead to the specific genetic factor(s) responsible for
(familial) AAA. Considering the supposed autosomal dominant inheritance, a gene mutation in one of the structural
proteins of the connective tissue is expected. In the future, linkage analysis may resolve the genetic background of AAA.
Key Words: Familial abdominal aortic aneurysm; Genetic aetiology; Candidate genes; Linkage analysis.
Introduction
Eur J Vasc Endovasc Surg 24, 105±116 (2002)
doi:10.1053/ejvs.2002.1692, available online at http://www.idealibrary.com onDespite improved diagnostic and therapeutic options,
patients with an aneurysm of the abdominal aorta
(AAA) still have an increased risk of mortality. In
screening programs the prevalence of an AAA,
defined by an infrarenal aortic diameter 30 mm
based on using ultrasound imaging, varied between
4.5 and 8% in men aged between 60 and 80 years.1,2
The incidence of new aneurysms, defined as an initial
aortic diameter smaller than 30 mm that has expanded
more than 5 mm in a 5.5 year period, is 3.5 per 1000
person-years (95% confidence interval (CI) 2.8±4.4).
The highest incidence, of new diagnosed aneurysms,
i.e. 5.2 (95% CI 3.7%±7.0), was found in men aged from
60±69 years.3
The aetiology of the AAA is assumed to be multi-
factorial. Positive associations with AAA includePlease address all correspondence to: C. J. van Vlijmen-van
Keulen, Department of Vascular Surgery, PO Box 7057, 1007 MB
Amsterdam, The Netherlands.
1078±5884/02/020105  12 $35.00/0 # 2002 Elsevier Science Ltd. Aage,4±7 smoking,7±13 and family history of AAA14±24,
whereas atherosclerotic disease, female sex, diabetes
and black race are negatively associated.9 Clifton, who
described familial AAA that affected three brothers of
one family, was the first to hypothesise that AAA
could be an inheritable disease.14
The purpose of this review is to give an overview of
research data on the genetic background of AAA.
Studies were evaluated that investigated familial
AAA by using family history or ultrasound examin-
ation. The outcome is discussed in relation with pre-
sent knowledge on the inheritance of AAA, the
candidate gene approach, and linkage analysis.
Methods
Using the words or MeSH terms aortic aneurysm
(abdominal), screening, aetiology, genetics (linkage),
extracellular matrix proteins, matrix metallopro-
teinases and tissue inhibitors of metalloproteinases,
we performed a computerised search for relevantll rights reserved.
The evaluation of familial occurrence of AAA
106 C. J. van Vlijmen-van Keulen et al.articles in MEDLINE, EMBASE, SUMsearch electronic
databases and the Cochrane library. We also searched
reference lists of review and original articles. We
limited our search to English language articles. We
included all available material untill April 2002.
We performed a systematic review for the subhead-
ing `` Family history and Ultrasound screening''.
Studies were included in the analysis if they had
used the following definitions:
 a positive family history, defined as one or more
first-degree relatives (FDR) with an AAA
mentioned by the patient and/or diagnosed by
a physician;
 ultrasonography for AAA, defined as an infrarenal
aortic diameter (IRD) greater than 30 mm, or
a diameter of 50% greater than the normal suprar-
enal aorta (SRD);
 studies had to compare the patient group with
a control group.
We calculated the odds ratios with corresponding
95% confidence intervals (95% CI).
Our findings are discussed in relation with current
knowledge on inheritance, candidate gene approach
and linkage analysis.
Results
Family history and ultrasound screening
In this systematic review, 29 candidate studies were
evaluated that investigated familial occurrence of
AAA by family history or ultrasound examination,
compared to a control group. Four articles fulfilled
our criteria (Table 1). Figure 1 shows that the odds
ratio for an AAA in first degree relatives mentioned
by the AAA patient is 9.7, with the 95% CI from
4 to 23.16,18 The odds ratio for siblings of AAA patients
is 4.1 (95% CI 1.5±11.2) and for the brothers 4.2 (95% CI
1.4±12.8).16,18,21
Using infrarenal aortic diameter based on ultra-
sound measurements, the siblings of AAA patients
have an odds ratio between 2.6 (95% CI 1.0±7.1) and
3.3 (95% CI 1.1±10.7).21,25 In the study of Baird et al.21
ultrasound examinations were done only for siblings
of the AAA patients. Controls themselves were exam-
ined, but not their siblings. In the study of Salo et al.
we calculated an odds ratio for brothers of AAA
patients of 8.1 (95% CI 1.8±37.5).25
Because these studies were of a cross-sectional
design, it is always uncertain whether any other rela-
tive will develop an AAA in the future.Eur J Vasc Endovasc Surg Vol 24, August 2002showed that AAA in siblings is significantly higher
than in the overall population, especially among the
male population of the same age, supporting that
AAA can be an inheritable disease.
Inheritance
Different models have been postulated regarding the
pattern of inheritance of AAA. Tilson and Seashore
studied the hereditary pattern of 50 families, among
these three pairs of identical twins. They suggested
that only one gene is responsible for AAA inheritance
which is likely to be autosomal dominant with
a strong bias toward male to female expression (8 : 1).
An X-linked inheritance pattern was ruled out based
on transmission of the disease from father to
son in four of the families included.26 Powell and
Greenhalgh on the other hand assumed a multifactorial
model and calculated a 70% inheritability from 60
patients, 25 with a positive family history, using the
threshold model for inheritability by Falconer.17,27
Majumber et al. collected data on first-degree relatives
of 91 probands. Thirteen families had at least one
affected FDR, one family had a proband with an
affected spouse and the remaining families were sim-
plex. The most likely genetic model was a recessive
gene at an autosomal diallelic major locus.28 Verloes
et al. assumed a single gene effect showing dominant
inheritance, with low penetrance.29 The latter two
authors noted that a multifactorial component did
not increase the likelihood of the data set significantly.
Data on family history for AAA collected in our pre-
vious study were in agreement with an autosomal
dominant inheritance with reduced penetrance.30
In all these family studies that investigated the
inheritance pattern of AAA no classic signs of any
known syndrome familiar with AAA, like the Marfan
or Ehlers Danlos type IV syndrome, could explain the
heredity pattern.
Since familial AAA may occur in two or three con-
secutive generations autosomal dominant is the most
likely pattern of inheritance.
Candidate genes
The candidate gene approach involves the character-
isation of mutations in the candidate gene. Possible
candidate genes may be genes encoding the compo-
nents of the extracellular matrix of the vascular wall.
This matrix mainly consists of collagen. Other candi-
date proteins are elastin, proteoglycans, fibrillin
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Eur J Vasc Endovasc Surg Vol 24, August 2002
Fig. 1 Odds ratios of a positive family history and/or ultrasound examination for AAA in individual studies. A positive family history
(FH) )is defined as one or more first-degree relative (FDR) with an AAA mentioned by the patient and/or diagnosed by a physician.
# AAA by ultrasonography (US) is defined as an infrarenal aortic diameter (IRD) greater than 30 mm, or a diameter of 50% greater than the
normal suprarenal aorta (SRD).
Siblings are the brothers and sisters of the AAA patient.
The odds ratio for individual trials is shown as dots, error bars indicate 95% CIs.
108 C. J. van Vlijmen-van Keulen et al.and many enzymes involving the post-translational
modification of structural proteins, the construction
of the matrix and proteases involved in turnover of
matrix components. Mutations in any of these
candidate genes may explain the hereditary back-
ground of AAA. Therefore mutation analysis of all
candidate genes is not an efficient approach. More-
over, we know from the classic hereditary connec-
tive tissue diseases, i.e. Marfan and Ehlers±Danlos
type IV syndrome, that every family has its own
gene mutation with typical clinical signs in affected
individuals.
We reviewed the genetics on familial AAA, sub-
divided in genes involved in the structural compo-
nents of the connective tissue of the aortic wall,
genes of the matrix-degrading enzymes, their inhibi-
tors, proteoglycans, and genes involved in the process
of atherosclerosis.Eur J Vasc Endovasc Surg Vol 24, August 2002Type III collagen
Collagen is the most common protein in humans,
providing the extracellular framework for all multi-
cellular organisms. The collagens are composed of a
triple helix of three identical polypeptide a-chains,
having a Gly-x-y repeating sequence, Gly means gly-
cine, x proline, and y another amino acid.31 Type III
collagen is abundant in the vessel wall and respon-
sible for the tensile strength of arteries.32
Abdominal aortic aneurysms, dissections and rup-
tures are common disorders in different syndromes
that are caused by collagen defects. Phenotypic over-
lap of heritable disorders of connective tissue might
be a possible explanation of familial aneurysms.33
Ehlers±Danlos type IV syndrome (EDS IV), i.e. the
vascular type, was first described by Barabas in 1967.34
This type is characterised by a sudden death from
rupture of the aorta and spontaneous dissections.
Familial Aortic Aneurysm 109EDS IV is caused by genetically determined type III
collagen (COL3A1) defect or a deficiency.
The hypothesis of familial AAA due to a type III
collagen deficiency was first suggested by Loosemore
et al. in 1987.35 To study directly the role of the type III
collagen gene Liu et al. produced type III collagen
knock-out mice. Heterozygous mutant mice had
about 50% reduction in type III collagen after protein
analysis whereas no type III collagen was detected in
homozygous mutant mice. The major cause of death
in these mutant mice was rupture of a major blood
vessel, similar to patients with EDS IV.36 In patients
with a family history for AAA lower amounts of type
III collagen in the aortic media were measured in
6±18% of the patients.23,37,38 However, gene mutations
were detected even if the biosynthesis of type III pro-
collagen was normal. Previously described type III
procollagen gene mutations and the amino acid sub-
stitutions responsible for familial AAA are Gly619Arg,
G1 IVS20, Gly136Arg and Leu002Phe. These muta-
tions influence the triple-helical domain of type III
procollagen and make the protein unstable.33,39±41
Another mutation, Thr501Pro, was found also in
healthy controls, but without influence on the triple-
helical domain of type III collagen.41
Additionally, an analysis of 50 patients indicated a
causal relation with mutations in the type III procolla-
gen in only 2% of aortic aneurysms.33,39 Deak et al.
measured an altered thermal stability of the type III
collagen trimer also indicating that the triple helical
conformation of type III collagen is imperfect.42
Powell et al. could not confirm their previous claim
that a mutation at amino acid 619 of glycine to argi-
nine was associated with aneurysms. They suggested
that the ageing aorta and changing mechanical stabi-
lity of the artery might be influenced by variations in
the type III collagen gene.43±45 In 1999 our own group
studied in a large family segregation of the type III
collagen gene and the presence of AAA. One allele
was found in all affected individuals and not in any of
the unaffected relatives. This resulted in LOD (loga-
rithm of the odds ratio) score of 1.5 with no recombina-
tion, so linkage with the type III collagen gene could
not be proven or excluded.23 In a subsequent study in
family members of the AAA patients the protein
analysis of cultured fibroblasts, used to measure the
type III/I collagen ratio, was normal in all FDR. No
evidence was found that a type III collagen deficiency
appears to be an etiologic factor in the development of
familial AAA.30 Evidence for an increased metabolism
of type III in AAAwas provided by Bode et al. Immuno-
histochemical staining with antibodies for the amino-
terminal propeptide of type III collagen (PIIINP),
which represents newly synthesised type III collagen,was mainly present in the media layer of AAA. They
suggested that the increased type III pN-collagen in
AAA might result from impaired fibril formation
causing aortic dilatation. In both AAA and athero-
sclerotic aorta's type I pN-collagen was present in
the intima, which type is suggested possibly related
to atherosclerotic changes.46
Sporadically, a type III collagen gene mutation is
responsible for familial AAA. It is therefore more like-
ly that collagen deficiency may result from defects
during posttranslational modification or from an
altered collagen metabolism.
Type I collagen, alpha 1 and 2
Type I collagen is a major constituent of the vessel
wall. However, mutations in the type I collagen,
alpha I (COL1A1) gene do not lead to vascular pro-
blems, except for easy bruising, but are the underlying
cause of all types of osteogenesis imperfecta (OI).47,48
Minion et al. reported an increase in type 1, alpha I,
procollagen expression in AAA but not in atheroscle-
rotic occlusive diseased or normal aortic tissue.49 They
gave no explanation for these matrix changes in the
dilated aorta. There is no evidence available indicating
that COL1A1 gene mutations are involved in aneur-
ysm formation.
Mutations in the type I collagen, alpha 2 (COL1A2)
gene are associated with OI and (rarely) forms of the
EDS.50±52 Vouyouka et al. demonstrated with a knock-
out mouse model that type I collagen, alpha 2, is
involved in the maintenance of biomechanical and
functional properties of the aorta. Circumferential
and longitudinal load-extension curves were used
for determination of maximum breaking strength
and incremental elastic modulus. The presence of
homotrimeric type I collagen isotype (knock out
mouse) significantly weakens the aorta. After histo-
logical analyses and hydroxyproline assays no signifi-
cant differences were found in type I collagen content
or organisation. The qualitative alterations appeared
more important than the quantitative differences in
collagen.53 These data may help to elucidate the role
of collagen in the development of aneurysmal aortic
disease or dissection.
Elastin
Elastin is synthesised by smooth muscle cells and pro-
vides the elastic properties of the artery. It is organised
in concentric lamellae and a progressive decrease in
number of the lamellae is observed from the heart to
the aorto-iliac bifurcation. Elastin is composed largely
of glycine, proline, and other hydrophobic residues
and contains multiple lysine-derived crosslinks, such
as desmosines, which link the individual polypeptideEur J Vasc Endovasc Surg Vol 24, August 2002
Table 2. MMPs expressed and produced in the inflammatory
process in the atherosclerotic aneurysmal wall and the substrates.
Enzyme Substrate
MMP1 (interstitial collagenase) Collagen type I and III
MMP3 (stromelysin) Proteoglycans, laminin,
fibronectin, collagen
type IV, V, IX, and X, and
enhances activity of MMP1
MMP2 (72-kD gelatinase/
gelatinase A)
Denatured collagen,
collagen type
MMP9 (92-kD gelatinase/
gelatinase B)
IV, V, VII, and X, and
elastin
MMP7 (matrilysin) Gelatin, laminin, fibronectin,
type IV collagen, versican,
and elastin
MMP12 (macrophage
metalloelastase)
Elastin
MMP means matrix metalloproteinase.
110 C. J. van Vlijmen-van Keulen et al.chains into a rubberlike network. The hydrophobic
regions of the chains, situated between the crosslinks,
are highly mobile.
Tropoelastin is the soluble precursor of elastin. The
tropoelastin molecules are deposited into a micro-
fibrillar structure that contain fibrillin-1 and 2 as the
main components.54 The amount of elastic tissue in
the aortic wall appears to be gradually lost by ageing.
However, the presence of low levels of tropoelastin
mRNA in adult aorta's suggests that there is some
continued elastin synthesis for growth and main-
tenance.55,56 Many authors found a more pronounced
decrease than can be attributed to aging.56±59 A syn-
drome with mutations in the elastin gene is the
Williams-Beuren syndrome (elfin facies), the pheno-
type is an autosomal dominant supravalvular
aortic stenosis. This syndrome is not associated with
AAA.60,61 Boyd's research group (personal communi-
cation62) created a transgenic mouse with a deletion of
exons 19±31 in the tropoelastin gene. The hetero-
zygous founder suddenly died at 7 months of age.
Autopsy findings were consistent with the hypothesis
that death was due to rupture of an aneurysm of the
aorta, suggesting that mutation in the gene of elastin
may be associated with aneurysm disease in a trans-
genic model.31 The long half-life of elastin and the
low levels of tropoelastin mRNA may indicate that
the loss of elastin is due to elastolysis. Summarising
these studies, we can conclude that there is no
clear evidence that mutations in the elastin gene are
responsible for FAAA.
Fibrillin
The peripheral microfibrillar network that surrounds
the core of the elastin largely consists of fibrillin and
plays a critical role in the integrity of the aortic wall.
Mutations in the fibrillin-1 gene are responsible for
Marfan syndrome. The Marfan syndrome is a herit-
able disorder of connective tissue with skeletal, ocular
and cardiovascular complications.63
Cardiovascular problems are mitral valve prolapse,
aortic dilatation and aortic dissections. Nicod et al. and
Milewicz et al. described families with aortic dissect-
ing aneurysm or aortic dilatation at a young age of
which none was related to the Marfan syndrome.
They suggested a genetically determined disease of
autosomal dominant inheritance with variable expres-
sion and reduced penetrance. The vascular complica-
tions were assumed probably caused by single gene
mutation in absence of an associated syndrome.64±66 In
1995 Francke et al. studied families with ascending
aortic disease, aneurysms and dissection, none of
them had Marfan syndrome. They found a Gly1127Ser
mutation of the fibrillin-1 gene and suggested that thisEur J Vasc Endovasc Surg Vol 24, August 2002mutation might be responsible for reduced matrix
deposition, with weakening of the elastic tissue. The
clinical features of this amino acid substitution is less
drastically than seen with substitutions of cysteine or
other amino acids that cause a classic Marfan syn-
drome. This predisposes to ascending aortic dilatation
later in life.67 Powell et al. focused on blood pressure
and fibrillin-1 genotype. Variation in the fibrillin-1
gene modulates the elastic properties of the ageing
aorta which influences arterial pulse pressure. They
postulated that the combination of the environmental
risk factor, (untreated) hypertension and a genetic risk
factor (variation in the fibrillin-1 gene) influences the
development of aneurysmal disease.45,68 By means of
gene-targeting mutation of fibrillin-1 in a mouse
model, Pereira et al. showed that an underexpression
of fibrillin-1 could lead to an inflammatory fibroproli-
ferative response and the formation of aortic aneur-
ysms.69 In summary it can be concluded that gene
mutations in the fibrillin-1 gene are associated with
familial thoracic aortic aneurysms (TAAA) and dissec-
tions, with no signs of a Marfan syndrome. The asso-
ciation with familial abdominal aortic aneurysms
needs more profound investigation.
Matrix proteinases and tissue inhibitor
metalloproteinases
The matrix metalloproteinases (MMPs) are a family of
related matrix-degrading enzymes that are important
in tissue remodelling and repair. Abnormal expression
is associated with various diseases such as tumor
invasiveness, inflammatory processes and athero-
sclerosis. Enzymatic degradation of structural matrix
proteins is said to contribute to the pathogenesis of
AAA.70±76 Activated MMPs weaken the aortic media,
as they cause destruction of elastic fibres and smooth
Familial Aortic Aneurysm 111muscle cells.37,58 Most of the MMPs are expressed in
macrophages, the major inflammatory cells respon-
sible for matrix degradation. Busutill et al. first men-
tioned elastase and collagenase activity in the human
aorta.77,78 Table 2 recite the most expressed and
produced MMPs in the inflammatory process in the
atherosclerotic aneurysmal wall.71,79±84
The MMPs are acting as a cascade, starting with
MMP1, to mediate the degradation of aortic wall elas-
tic fibres.85 Increased expression of MMP9 is mea-
sured in AAA at both the messenger RNA and
protein levels.86,87 MMP9 levels in plasma are asso-
ciated with size and expansion of the AAA.72 Studies
using cDNA microarrays reported an upregulation of
MMP9 gene expression in AAA versus healthy aorta.
MMP9 was also upregulated in atherosclerotic
aorta.88,89 MMP9 is localised to the adventitia and
adventitial side of the tunica media in AAA tissue
and in the intima and intimal side of the media
in atherosclerotic occlusive aorta tissue.90 There is
evidence, although not conclusive, that the 5A allele
of MMP3 is a risk factor for AAA among Finnish
patients.91 Studies reported increased production
of MMP13, MMP2, MMP12 and membrane type-1
(MT-1) MMP in human aneurysmal tissue compared
to atherosclerotic-and normal aortic tissue.70,92±94 MT-1
MMP activates pro-MMP2, which is proteolytically
processed to the MMP2 active form. Increased levels
of MMP13, 2 and 12 play a role in the collagen and
elastin degradation and therefore they could have a
role in aneurysmal disease.
The serine proteases include plasmin, thrombin,
urokinase-(u-PA) and tissue-type-plasminogen activa-
tor (t-PA). Plasmin is activated by u-PA and t-PA and
activates MMP1 and MMP9. Leakage of plasmin from
a large mural thrombus to the AAA may lead to
accelerated matrix destruction and rapid aneurysm
enlargement.95
Rossaak et al. found in patients with familial
AAA, a significantly different allele frequency for
plasminogen activator inhibitor-1 (PAI-1; 4G-allele)
compared with non-familial AAA patients and con-
trols. The 4G homozygous variant is associated
with increased PAI-1 expression and consequently
reduced plasmin activity and therefore may be
selected against in-familial AAA.96 These results
were in contrast with that reported by Yoon et al.,
who found no significant difference, between AAA
patients and controls in PAI-1 genotype and allele
frequencies.91
Because apolipoprotein E (apoE) is a ligand for
receptors that clears remnants of chylomicrons and
very low density lipoproteins, lack of apoE would
be expected to cause accumulation in plasma ofcholesterol-rich remnants which prolonged circulation
could be atherogenic.97±99 Gerdes et al. suggest that the
common polymorphism of the apoE genotype influ-
ences the AAA expansion rate.100 ApoE and u-PA
deficient mice were protected for aneurysm formation,
probably because there was less plasmin to activate
the pro-MMPs.101
Cysteine proteases, i.e. cathepsin S and K,
regulate the intracellular protein degradation and
turnover.85 They are localised in smooth muscle cells
and macrophages within atherosclerotic plaques.102
Lysosomal proteases, i.e. cathepsin D, H and L, are
involved in the degradation of structural proteins and
were found to have higher activities in aneurysmal
wall and mural thrombus than in the normal aortic
wall.88,103 These cathepsins can mediate extensive
matrix breakdown, thereby negatively influencing
the elasticity and mechanical resistance of the
aortic wall.
The most abundant extracellular inhibitor of the
cysteine proteases is cystatin C. Increased aneurysm
size and expansion rate are associated with cystatin C
deficiency.104
The tissue inhibitors of metalloproteinases (TIMPs)
are major inhibitors of several enzymes that are
destructive to connective tissue. Brophy et al. reported
a decrease of TIMP in AAA tissue. This may contrib-
ute to the increased proteolysis observed in AAA.105
Quantifying relative mRNA levels resulted in a
higher ratio of MMP mRNA amount to TIMP mRNA
in AAA than seen in normal aortas.106 No mutations
were found in the TIMP 1 or 2 genes in aneurysm
patients.107,108
Several cytokines, i.e. interleukin-1b, tumor necrosis
factor-a, and interleukin-6, are suggested influencing
the integrity of the aortic wall resulting in degenera-
tive as well as inflammatory aneurysms.84,94,109±111
Interleukin-1b causes an increased matrix turnover
in aneurysms through its effect on smooth muscle
cell collagenase and collagen gene expression.76
Due to the inflammatory component, elastin frag-
ments trigger the migration of macrophages leading
to interleukin-1b production, which can change
the gene products of the aortic smooth muscle cells
leading to collagenase production. Collagenase acti-
vity is detectable in the ruptured aneurysm wall.38,78
The concentration of interleukin-6 is influenced by
the genotype. In patients with small AAA, the 174G/C
polymorphism of the interleukin-6 gene predicts
future cardiovascular mortality.111 It remains difficult
to establish whether the higher circulating concentra-
tions of cytokines are caused by or a consequence of
AAA or may be due to other causes, i.e. malignancy,
infection or atherosclerosis.Eur J Vasc Endovasc Surg Vol 24, August 2002
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lated by the human leukocyte antigen (HLA) class II
genes. HLA alleles have been suggested to act as
genetic risk factors for AAA.112,113 Hirose et al. sug-
gests that HLA-DQ3 antigen appeared to have a pro-
tective effect114 in relation to AAA, whereas HLA
DR15 actually promotes AAA disease.115
Recently Unno et al. detected more gene mutations
in plasma platelet activating factor (PAF) acetylhydro-
lase in Japanese AAA patients than in controls. The
authors hypothesize that deficiency of PAF acetylhy-
drolase may fail to inactivate PAF, thereby accelerat-
ing inflammation and MMP production, which may
contribute to the development of AAA.116
There is ample evidence that the degradation of
extracellular matrix proteins leads to aneurysm for-
mation of the abdominal aorta. The question remains
if there is a specific MMP responsible for aneurysm
formation. More likely this process is caused by a
variety of proteins in the cascade of matrix turnover.
Other candidate genes
Genes of haptoglobin alpha chain (HP) and
cholesterol-ester transfer protein (CETP) are located
on the long arm of chromosome 16. Variations at the
HP locus might have a direct effect on the degradation
of elastin in the atherosclerotic aorta, whereas varia-
tions at the CETP locus could affect the lipoprotein
metabolism and might therefore alter the susceptibil-
ity to atherosclerosis. Powell et al. first mentioned that
HPs containing an alpha 1-chain accelerate the deg-
radation by elastases of aortic elastin in vitro two- to
four-fold. An increase of the frequency of a rare poly-
morphism at the CETP locus in aneurysm patients
suggests that variations in these proteins influences
dilatation of the abdominal aorta.117 Later they were
unable to confirm that HP might be informative as a
marker for screening in familial AAA.43 Also Rambot-
tom et al. were not able to detect CETP and HP micro-
satellite polymorphism.118
Kuivaniemi et al. findings exclude mutations in the
coding sequence of fibulin 2, an extracellular matrix
protein, as a major cause of AAA, but they suggest
that fibulin-2 exhibits a high degree of sequence
variability.119
Alpha1-Antitrypsin, an elastase inhibitor, could not
be detected as a gene-disease marker in plasma.118 No
relation was found with alpha1-antitrypsin deficiency
and AAA using monoclonal-antibody ELISA tests.120
Biglycan and decorin are proteoglycans, found in
many connective tissues, are synthesised by smooth
muscle cells. They play a role in stabilising the struc-
ture of collagen fibres. Changes in the production
and/or the function of these proteoglycans could beEur J Vasc Endovasc Surg Vol 24, August 2002responsible for matrix alterations and weakening of
the vascular wall. Tamarina et al. found a 15-fold
decrease in biglycan mRNA expression in AAA com-
pared with normal aortas. The decorin mRNA expres-
sion was unchanged.87 Tung et al. found an increased
decorin expression whereas Armstrong et al. found no
changed expression in their gene array evaluation of
AAA.88,89 In contrast Melrose et al. found elevated
levels of biglycan and other heparan sulfate proteo-
glycans in smooth muscle culture of AAA tissue.121 It
is disputable whether biglycan plays an important
role in the integrity of the aortic wall. Xu et al. gener-
ated biglycan deficient mice that seemed normal at
birth but displayed a phenotype characterised by
reduced growth rate and decreased bone mass, but
no vascular abnormalities were found.122
Hyperhomocysteinemia due to alterations in
the homocysteine metabolism is a risk factor for
(premature) atherosclerotic disease.123 Brunelli et al.
measured elevated homocysteine levels in patients
with and without evidence of atherosclerotic local-
isations compared with controls. A mutation in the
5,10-methylenetetrahydrofolate reductase (MTHFR)
coding sequence has been associated with reduced
specific MTHFR activity and elevated homocysteine
levels.124 The genotype distribution of the C677T
MTHFR mutation was not significantly different in
the AAA patients compared with controls.125
Linkage analysis
The candidate gene approach might give us more
insight in the pathology of AAA but does not lead to
the specific genetic factor(s) responsible for (familial)
AAA. A disadvantage of candidate gene approach is
that the investigated proteins are functioning in a very
complex process of construction and degradation in
the ageing abdominal aortic wall. Pathological synthe-
sis of one of these components may result from defects
during post-translational modification or from an
altered protein metabolism. On the other hand, link-
age analysis gives an indication of chromosomal local-
isation, but no information on the function. Linkage of
a disease phenotype, with a DNA marker of known
chromosomal location, means that the two are located
in close proximity on the DNA. Cross-overs happen
most of the time during meiosis. Meiotic recombina-
tion frequencies of less than 50% indicate that the
disease phenotype and the marker are linked. Linkage
can be established whenever the phenotype and geno-
type of related individuals is analysed, therefore link-
age can be established by analysing large families or
by analysing pairs of siblings. AAA is a late onset
Familial Aortic Aneurysm 113disease and in most cases only one generation is
affected, because the parents have died and the child-
ren are too young to develop an AAA. A further
problem is that siblings of AAA patients can develop
AAA later in life. To eliminate the problem of late-
onset disease an affected sib-pair analysis can be
performed.126 Linked loci are further examined
to detect the genes involved in the pathology of
familial AAA.
Guo et al. performed linkage analysis of patients
with familial thoracic aortic aneurysms (TAA) and
dissections. A major locus for familial TAA and dis-
sections mapped to chromosome 5q13-14, with the
majority of the families (9 of 15) identified, demon-
strating evidence of linkage to this locus. Linkage
analysis of the other six families did not demonstrate
evidence of a linkage to any loci previously associated
with aneurysm formation.127According to the authors,
genes mapped to the chromosome 5q13-14 region
are thought to be poor candidates for the defective
gene involved in TAAs/dissections because of
there function. In our opinion, in this region the
betaine-homocysteine methyltransferase gene may be
a possible candidate. Betaine-homocysteine methyl-
transferase catalyses the conversion of betaine and
homocysteine to dimethylglycine and methionine.
Hyperhomocysteinemia is a risk factor for arterial
occlusive disease, but probably also for aneurysmal
disease.123,125,128,129
Scientists from Wayne State University in Detroit, in
collaboration with scientists from other universities,
already started an affected sib-pair DNA linkage
analysis to identify AAA susceptible gene(s).130
Conclusion
The siblings of AAA patients, especially among the
brothers, are significantly more affected, supporting
that AAA can be an inheritable disease.
A lot of questions in the genetics of familial AAA
remain unanswered. The inheritance is most likely to
be autosomal dominant with incomplete penetrance.
Therefore deficiencies or gene mutations of proteins of
the structural components of the connective tissue are
likely responsible for susceptibility to AAA. Defects
during post-translational modification or from an
altered protein metabolism are possible alternative
explanations, but enzyme deficiencies are more likely
to show recessive inheritance. AAA is a possible gen-
etically heterogeneous condition. A small number of
families have a mutation in COL3A1, indicating that
AAA in some cases may be considered a subclinical
manifestation of EDS IV. Disturbed regulation ofproteases, i.e. MMP2, 3 and 9, influencing the balance
in tissue remodelling and repair, must be considered
as an important factor in the pathogenesis of AAA.
More studies need to be done to investigate if changes
in gene expression, activation of the proenzyme forms
of the MMP's or competition with the TIMP's are
responsible for the imbalance in tissue architecture.
In the future, linkage analysis, may resolve the genetic
background of AAA. Genetic studies may define sub-
groups of patients at risk for familial AAA who would
benefit most from ultrasound screenings programmes.
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